Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day
Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final...
Michael Amoroso Precision Biosciences Inc Drug Administration Precision Biosciences Typeb End Alan List
Source: marketscreener.com